KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Aquestive Therapeutics (AQST) Other Accumulated Expenses: 2017-2020

Historic Other Accumulated Expenses for Aquestive Therapeutics (AQST) over the last 3 years, with Dec 2020 value amounting to $201,000.

  • Aquestive Therapeutics' Other Accumulated Expenses fell 17.28% to $201,000 in Q4 2020 from the same period last year, while for Dec 2020 it was $201,000, marking a year-over-year decrease of 17.28%. This contributed to the annual value of $201,000 for FY2020, which is 17.28% down from last year.
  • According to the latest figures from Q4 2020, Aquestive Therapeutics' Other Accumulated Expenses is $201,000, which was down 29.23% from $284,000 recorded in Q3 2020.
  • Aquestive Therapeutics' 5-year Other Accumulated Expenses high stood at $284,000 for Q3 2020, and its period low was $97,000 during Q1 2020.
  • For the 3-year period, Aquestive Therapeutics' Other Accumulated Expenses averaged around $212,909, with its median value being $207,000 (2018).
  • Within the past 5 years, the most significant YoY rise in Aquestive Therapeutics' Other Accumulated Expenses was 54.35% (2020), while the steepest drop was 49.48% (2020).
  • Aquestive Therapeutics' Other Accumulated Expenses (Quarterly) stood at $225,000 in 2017, then declined by 8.00% to $207,000 in 2018, then increased by 17.39% to $243,000 in 2019, then fell by 17.28% to $201,000 in 2020.
  • Its Other Accumulated Expenses was $201,000 in Q4 2020, compared to $284,000 in Q3 2020 and $223,000 in Q2 2020.